SWOG clinical trial number
S0601

A Phase II Study of Combination Rituximab-CHOP and Bortezomib (Velcade) (R-CHOP-V) Induction Therapy Followed by Bortezomib Maintenance (VM) Therapy for Patients With Newly Diagnosed Mantle Cell Lymphoma

100% Accrual
Accrual
100%
Closed
Phase
100% Accrual
Accrual
100%
Published
Abbreviated Title
NON-HODGKINS: R-CHOP-V followed by VM maintenance therapy for MCL
Activated
08/15/2006
Closed
06/01/2008
Participants
NCORP, Members, Medical Oncologists, Pathologists, Affiliates

Research committees

Lymphoma

Treatment

Rituximab Bortezomib CHOP

Other Clinical Trials

S2308
SWOG Clinical Trial Number
Research Committee(s)
Lymphoma
Activated
08/01/2024
21% Accrual
Accrual
21%
Open
Phase
CTSU/AHOD2131
SWOG Clinical Trial Number